Literature DB >> 2566381

Guanfacine treatment of Alzheimer's disease.

J Schlegel1, E Mohr, J Williams, U Mann, M Gearing, T N Chase.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2566381     DOI： 10.1097/00002826-198904000-00007

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  8 in total

Review 1.  The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.

Authors:  A D Lawrence; B J Sahakian
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

Review 2.  Neurotransmitter replacement therapy in Alzheimer's disease.

Authors:  E Mohr; T Mendis; I N Rusk; J D Grimes
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

Review 3.  Diagnostic and pharmacological approaches in Alzheimer's disease.

Authors:  C Hermann; R G Stern; M F Losonzcy; S Jaff; M Davidson
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

Review 4.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  J C Soares; S Gershon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

Review 5.  Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps.

Authors:  Raymond T Bartus; Reginald L Dean
Journal:  Psychopharmacology (Berl)       Date:  2008-11-15       Impact factor: 4.530

Review 6.  New approaches for the quantification and targeting of noradrenergic dysfunction in Alzheimer's disease.

Authors:  Michael David; Paresh A Malhotra
Journal:  Ann Clin Transl Neurol       Date:  2022-03-15       Impact factor: 4.511

7.  Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments.

Authors:  Karen Hoang; Hilary Watt; Mara Golemme; Richard J Perry; Craig Ritchie; Danielle Wilson; James Pickett; Chris Fox; Robert Howard; Paresh A Malhotra
Journal:  Trials       Date:  2022-08-01       Impact factor: 2.728

8.  Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis.

Authors:  Michael C B David; Martina Del Giovane; Kathy Y Liu; Benjamin Gostick; James Benedict Rowe; Imafidon Oboh; Robert Howard; Paresh A Malhotra
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-07-05       Impact factor: 13.654
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.